Latest On Seres Therapeutics, Inc (MCRB):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 17:25 EST | News | Seres receives $125M milestone payment for FDA Approval of Vowst for C. difficile Infection | N/A |  |
| 2023-05-23 14:58 EST | News | Seres Q1 Earnings: Major News For Investors | N/A | |
| 2023-05-23 00:11 EST | News | Seres Therapeutics: Still Work To Do Before Realizing Its Potential | N/A | |
| 2023-05-09 15:43 EST | News | Seres Therapeutics GAAP EPS of -$0.57 misses by $0.02 | N/A | |
| 2023-05-09 15:42 EST | News | Seres Therapeutics, Inc. (MCRB) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-09 01:59 EST | News | Seres Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-05-03 13:01 EST | News | Seres Gets FDA Approval And The Share Price Goes Down! | N/A | |
| 2023-04-27 07:33 EST | News | Seres adds 11% on FDA nod microbiome therapy | N/A | |
| 2023-04-22 20:35 EST | News | Stocks To Watch: Microsoft, Amazon And Coca-Cola Headline Huge Earnings Week | N/A | |
| 2023-04-17 23:40 EST | News | Seres hits four-month high ahead of FDA decision on lead asset | N/A | |
| 2023-04-06 00:47 EST | News | Seres Therapeutics: Binary Catalyst Unlocking | N/A | |
| 2023-03-07 21:52 EST | News | Seres Therapeutics GAAP EPS of -$2.31 misses by $0.15, revenue of $7.13M misses by $6.62M | N/A | |
| 2023-03-07 21:52 EST | News | Seres Therapeutics falls 9% on full-year earnings miss | N/A | |
| 2023-03-07 21:51 EST | News | Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-06 16:34 EST | News | Seres Therapeutics FY 2022 Earnings Preview | N/A | |
| 2023-02-06 20:00 EST | News | Seres Therapeutics: FDA Approval Straight Ahead | N/A | |
| 2023-02-05 18:02 EST | News | The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid | N/A | |
| 2022-12-09 21:16 EST | News | Seres Therapeutics (MCRB) Investor Presentation - Slideshow | N/A | |
| 2022-11-10 19:57 EST | News | Seres Gets Closer To Good Times | N/A | |
| 2022-11-02 20:10 EST | News | Seres Therapeutics GAAP EPS of -$0.49 misses by $0.02, revenue of $3.44M misses by $3.57M | N/A | |
| 2022-11-02 20:10 EST | News | Seres stock sinks as Q3 plunges in loss | N/A | |
| 2022-11-02 20:10 EST | News | Seres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-10-26 19:58 EST | News | Seres microbiome therapy for bacterial infection gets FDA priority review | N/A | |
| 2022-09-07 21:20 EST | News | Seres completes regulatory submissions seeking FDA nod for lead asset | N/A | |
| 2022-08-20 04:43 EST | News | Seres Therapeutics: What The Market Is Missing | N/A | |
| 2022-08-03 23:17 EST | News | Seres rises 16% as co expects to file BLA for C. difficile infection treatment in coming weeks | N/A | |
| 2022-08-03 23:17 EST | News | Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-03 08:18 EST | News | Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M | N/A | |
| 2022-07-13 04:02 EST | News | Seres Therapeutics: The Good And The Challenging | N/A | |
| 2022-06-30 13:41 EST | News | Seres Therapeutics stock slips on $100M stock offering | N/A | |
| 2022-06-11 04:19 EST | News | Seres Therapeutics: The Pipeline Is The Problem | N/A | |
| 2022-06-09 19:45 EST | News | Seres Therapeutics: As Biotech Fades, The Case For The Company's Investment Strengthens | N/A | |
| 2022-06-07 14:32 EST | News | Seres Therapeutics posts additional safety data for lead candidate | N/A | |
| 2022-05-05 06:07 EST | News | Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-04 09:15 EST | News | Seres Therapeutics GAAP EPS of -$0.61 misses by $0.09, revenue of $1.49M | N/A | |
| 2022-05-03 17:34 EST | News | Seres Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-03-06 11:37 EST | News | Seres Therapeutics Is Playing A Long Game | N/A | |
| 2022-03-02 20:11 EST | News | Seres Therapeutics (MCRB) Presents At Chardan's Microbiome and Metagenomics Summit - Slideshow | N/A | |
| 2022-03-02 03:42 EST | News | Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-01 09:35 EST | News | Seres Therapeutics GAAP EPS of -$0.72 misses by $0.10, revenue of $144.92M misses by $4.9M | N/A | |
| 2022-01-20 06:51 EST | News | Seres late-stage data on microbiome therapy shows efficacy against C. difficile infection | N/A | |
| 2021-12-01 04:59 EST | News | Seres Therapeutics at a four-month high after update on study for microbiome drug | N/A | |
| 2021-11-11 09:21 EST | News | Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-11 09:21 EST | News | Seres Therapeutics shares surge 30% after Q3 earnings beat | N/A | |
| 2021-11-10 11:48 EST | News | Seres Therapeutics EPS beats by $0.75, beats on revenue | N/A | |
| 2021-11-10 11:47 EST | News | Seres Therapeutics and Bacthera ink collaboration agreement | N/A | |
| 2021-11-10 11:47 EST | News | Red Light For Seres Therapeutics, But Not A Stop Light For Me | N/A | |
| 2021-11-09 12:47 EST | News | Seres Therapeutics Q3 2021 Earnings Preview | N/A | |
| 2021-10-04 08:40 EST | News | Seres Therapeutics reports data from late-stage SER-109 study at IDWeek2021 | N/A | |
| 2021-10-04 08:38 EST | News | Seres Therapeutics Molecular Data On SER-109 Looks Good | N/A | |
About Seres Therapeutics, Inc (MCRB):
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
General
- Name Seres Therapeutics, Inc
- Symbol MCRB
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 155
- Fiscal Year EndDecember
- IPO Date2015-06-26
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.serestherapeutics.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 48.74
- Price/Book (Most Recent Quarter) 10.63
- Enterprise Value Revenue 49.52
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.42
- Next Year EPS Estimate -$1.30
- Next Quarter EPS Estimate -$0.31
- Profit Margin -268%
- Operating Margin -265%
- Return on Assets -23%
- Return on Equity -141%
- Revenue 33.22 million
- Earnings Per Share -$1.87
- Revenue Per Share $0.42
- Gross Profit -57355000
- Quarterly Earnings Growth 130.4%
View More
Highlights
- Market Capitalization 1.9 billion
- EBITDA -69997000
- PE Ratio -0.75
- PEG Ratio -0.11
- Analyst Target Price $37.57
- Book Value Per Share $1.91
View More
Share Statistics
- Shares Outstanding 91.55 million
- Shares Float 68.32 million
- % Held by Insiders 926%
- % Held by Institutions 81.2%
- Shares Short 6.56 million
- Shares Short Prior Month 5.96 million
- Short Ratio 7.17
- Short % of Float 12%
- Short % of Shares Outstanding 7%
View More
Technicals
- Beta 3.96
- 52 Week High $38.5
- 52 Week Low $3.01
- 50 Day Moving Average 22.75
- 200 Day Moving Average 26.66
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Seres Therapeutics, Inc (MCRB) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Seres Therapeutics, Inc (MCRB) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-02 | $17.56 million | -$0.19 | -$0.28 | 32.14% |
| 2020-09-30 | 2020-11-09 | $N/A | -$0.36 | -$0.26 | -40.46% |
| 2020-06-30 | 2020-07-28 | $6.05 million | -$0.28 | -$0.26 | -8.28% |
| 2020-03-31 | 2020-05-07 | $8.19 million | -$0.28 | -$0.26 | -7.69% |
| 2019-12-31 | 2020-03-02 | $7.62 million | -$0.25 | -$0.28 | 10.17% |
| 2019-09-30 | 2019-11-05 | $7.03 million | -$0.23 | -$0.28 | 18.35% |
| 2019-06-30 | 2019-08-06 | $12.53 million | -$0.24 | -$0.48 | 50.39% |
| 2019-03-31 | 2019-05-02 | $7.32 million | -$0.59 | -$0.44 | -33.57% |
| 2018-12-31 | 2019-03-06 | $10.63 million | -$0.52 | -$0.69 | 24.91% |
| 2018-09-30 | 2018-11-08 | $9.06 million | -$0.54 | -$0.63 | 14.83% |
| 2018-06-30 | 2018-08-02 | $4.61 million | -$0.68 | -$0.72 | 5.78% |
| 2018-03-31 | 2018-05-09 | $3.97 million | -$0.69 | -$0.76 | 9.69% |
| 2017-12-31 | 2018-03-08 | $3.06 million | -$0.72 | -$0.75 | 4.18% |
| 2017-09-30 | 2017-11-08 | $23.02 million | -$0.17 | -$0.56 | 69.64% |
| 2017-06-30 | 2017-08-03 | $3.01 million | -$0.69 | -$0.64 | -8.15% |
| 2017-03-31 | 2017-05-04 | $3.02 million | -$0.63 | -$0.66 | 4.79% |
| 2016-12-31 | 2017-03-16 | $3.04 million | -$0.64 | -$0.75 | 14.29% |
| 2016-09-30 | 2016-11-10 | $13.02 million | -$0.46 | -$0.56 | 17.37% |
| 2016-06-30 | 2016-08-11 | $3 million | -$0.70 | -$0.45 | -55.56% |
| 2016-03-31 | 2016-05-16 | $2.71 million | -$0.50 | -$0.48 | -4.89% |
| 2015-12-31 | 2016-02-25 | $N/A | -$0.41 | -$0.43 | 3.53% |
| 2015-09-30 | 2015-11-10 | $N/A | -$0.38 | -$0.32 | -18.75% |
| 2015-06-30 | 2015-07-01 | $N/A | -$1.45 | -$0.30 | -383.33% |
Seres Therapeutics, Inc (MCRB) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Seres Therapeutics, Inc (MCRB) Chart:
Seres Therapeutics, Inc (MCRB) News:
Below you will find a list of latest news for Seres Therapeutics, Inc (MCRB) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Seres Therapeutics, Inc (MCRB) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-04-17 | 0.5 | 0.55 | CALL | 1 | 65 | 122.97 | TRUE | 0.55 | 0 |
| 2025-04-17 | 1 | 0.4 | CALL | 1 | 30 | 150.55 | FALSE | 0.4 | 0 |
| 2025-04-17 | 1.5 | 0.05 | CALL | 1 | 0 | 61.38 | FALSE | 0.05 | 0 |
| 2025-04-17 | 2 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-04-17 | 2.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-04-17 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-04-17 | 7.5 | 0.11 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2025-04-17 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-04-17 | 1 | 0.4 | PUT | 0 | 7 | 0 | TRUE | 0 | 0 |
| 2025-04-17 | 1.5 | 0 | PUT | 0 | 0 | 141.09 | TRUE | 0 | 0 |
| 2025-04-17 | 2 | 0 | PUT | 0 | 0 | 159.41 | TRUE | 0 | 0 |
| 2025-04-17 | 2.5 | 0 | PUT | 0 | 0 | 187.89 | TRUE | 0 | 0 |
| 2025-04-17 | 5 | 0 | PUT | 0 | 0 | 197.13 | TRUE | 0 | 0 |
| 2025-04-17 | 7.5 | 0 | PUT | 0 | 0 | 206.16 | TRUE | 0 | 0 |
| 2026-01-16 | 0.5 | 0.55 | CALL | 4 | 204 | 75.68 | TRUE | -0.2 | -0.27 |
| 2026-01-16 | 1 | 0.45 | CALL | 2 | 940 | 109.17 | FALSE | -0.65 | -0.59 |
| 2026-01-16 | 1.5 | 0.4 | CALL | 0 | 434 | 128.46 | FALSE | 0 | 0 |
| 2026-01-16 | 2 | 0.7 | CALL | 0 | 27 | 177.27 | FALSE | 0 | 0 |
| 2026-01-16 | 2.5 | 0.37 | CALL | 0 | 21 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 3 | 0.35 | CALL | 0 | 12 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 3.5 | 0.2 | CALL | 0 | 12 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 4 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 4.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 5 | 1.05 | CALL | 0 | 43 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 5.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 7.5 | 0.25 | CALL | 0 | 20 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 0.5 | 0.2 | PUT | 0 | 28 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 1 | 0.5 | PUT | 0 | 195 | 131.65 | TRUE | 0 | 0 |
| 2026-01-16 | 1.5 | 0.76 | PUT | 0 | 3 | 139.58 | TRUE | 0 | 0 |
| 2026-01-16 | 2 | 1.33 | PUT | 0 | 5 | 139.5 | TRUE | 0 | 0 |
| 2026-01-16 | 2.5 | 1.9 | PUT | 0 | 10 | 135.66 | TRUE | 0 | 0 |
| 2026-01-16 | 3 | 0 | PUT | 0 | 0 | 134.9 | TRUE | 0 | 0 |
| 2026-01-16 | 3.5 | 0 | PUT | 0 | 0 | 162.12 | TRUE | 0 | 0 |
| 2026-01-16 | 4 | 0 | PUT | 0 | 0 | 140.2 | TRUE | 0 | 0 |
| 2026-01-16 | 4.5 | 0 | PUT | 0 | 0 | 147.23 | TRUE | 0 | 0 |
| 2026-01-16 | 5 | 0 | PUT | 0 | 0 | 153.55 | TRUE | 0 | 0 |
| 2026-01-16 | 5.5 | 0 | PUT | 0 | 0 | 159.34 | TRUE | 0 | 0 |
| 2026-01-16 | 7.5 | 0 | PUT | 0 | 0 | 178.46 | TRUE | 0 | 0 |
| 2027-01-15 | 0.5 | 0.6 | CALL | 0 | 72 | 0 | TRUE | 0 | 0 |
| 2027-01-15 | 1 | 0.85 | CALL | 0 | 2 | 128.54 | FALSE | 0 | 0 |
| 2027-01-15 | 1.5 | 1.1 | CALL | 0 | 1 | 132.49 | FALSE | 0 | 0 |
| 2027-01-15 | 2 | 0 | CALL | 0 | 0 | 132.06 | FALSE | 0 | 0 |
| 2027-01-15 | 2.5 | 0 | CALL | 0 | 0 | 140.02 | FALSE | 0 | 0 |
| 2027-01-15 | 5 | 0.5 | CALL | 1 | 0 | 152.07 | FALSE | 0.5 | 0 |
| 2027-01-15 | 7.5 | 0.32 | CALL | 0 | 14 | 0 | FALSE | 0 | 0 |
| 2027-01-15 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2027-01-15 | 1 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2027-01-15 | 1.5 | 0 | PUT | 0 | 0 | 256.39 | TRUE | 0 | 0 |
| 2027-01-15 | 2 | 0 | PUT | 0 | 0 | 216.3 | TRUE | 0 | 0 |
| 2027-01-15 | 2.5 | 0 | PUT | 0 | 0 | 117.42 | TRUE | 0 | 0 |
| 2027-01-15 | 5 | 0 | PUT | 0 | 0 | 125.06 | TRUE | 0 | 0 |
| 2027-01-15 | 7.5 | 0 | PUT | 0 | 0 | 146.75 | TRUE | 0 | 0 |
Latest MCRB Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 300 | $2.765 |
| Jun 13, 2022 7:59 PM EST | 100 | $2.765 |
| Jun 13, 2022 7:59 PM EST | 100 | $2.76 |
| Jun 13, 2022 7:59 PM EST | 5 | $2.76 |
| Jun 13, 2022 7:59 PM EST | 200 | $2.765 |
Seres Therapeutics, Inc (MCRB) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320018111/0000899243-20-018111-index.htm |
| 2020-03-13 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1609809/000000000020002288/0000000000-20-002288-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000021545719006834/0000215457-19-006834-index.htm |
| 2019-07-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000021545719008320/0000215457-19-008320-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000031506619001315/0000315066-19-001315-index.htm |
| 2019-11-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000031506619001764/0000315066-19-001764-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000031506620001189/0000315066-20-001189-index.htm |
| 2020-09-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000031506620001720/0000315066-20-001720-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000083423720008241/0000834237-20-008241-index.htm |
| 2018-06-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018511/0000899243-18-018511-index.htm |
| 2018-06-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018512/0000899243-18-018512-index.htm |
| 2018-06-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018513/0000899243-18-018513-index.htm |
| 2018-06-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018515/0000899243-18-018515-index.htm |
| 2018-06-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018518/0000899243-18-018518-index.htm |
| 2018-06-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm |
| 2018-06-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018521/0000899243-18-018521-index.htm |
| 2018-06-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018522/0000899243-18-018522-index.htm |
| 2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm |
| 2018-07-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm |
| 2018-07-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/0000899243-18-019814-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318020074/0000899243-18-020074-index.htm |
| 2018-09-04 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318023727/0000899243-18-023727-index.htm |
| 2018-09-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318023729/0000899243-18-023729-index.htm |
| 2018-09-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/0000899243-18-023938-index.htm |
| 2018-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318024194/0000899243-18-024194-index.htm |
| 2018-09-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm |
| 2018-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318026790/0000899243-18-026790-index.htm |
| 2018-10-24 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318027398/0000899243-18-027398-index.htm |
| 2018-10-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318027399/0000899243-18-027399-index.htm |
| 2018-11-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318029310/0000899243-18-029310-index.htm |
| 2018-12-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/0000899243-18-031411-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002136/0000899243-19-002136-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002137/0000899243-19-002137-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002138/0000899243-19-002138-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002141/0000899243-19-002141-index.htm |
| 2019-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002142/0000899243-19-002142-index.htm |
| 2019-02-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319003202/0000899243-19-003202-index.htm |
| 2019-02-15 | 3/A | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319003843/0000899243-19-003843-index.htm |
| 2019-04-24 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319011035/0000899243-19-011035-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017010/0000899243-19-017010-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017012/0000899243-19-017012-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017013/0000899243-19-017013-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017016/0000899243-19-017016-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017018/0000899243-19-017018-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017019/0000899243-19-017019-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017029/0000899243-19-017029-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017036/0000899243-19-017036-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017038/0000899243-19-017038-index.htm |
| 2019-06-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017640/0000899243-19-017640-index.htm |
| 2019-06-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319018536/0000899243-19-018536-index.htm |
| 2019-08-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319021169/0000899243-19-021169-index.htm |
| 2019-08-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319021170/0000899243-19-021170-index.htm |
| 2019-11-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924319028069/0000899243-19-028069-index.htm |
| 2020-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002210/0000899243-20-002210-index.htm |
| 2020-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002211/0000899243-20-002211-index.htm |
| 2020-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002212/0000899243-20-002212-index.htm |
| 2020-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002213/0000899243-20-002213-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002418/0000899243-20-002418-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002419/0000899243-20-002419-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002420/0000899243-20-002420-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002422/0000899243-20-002422-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002423/0000899243-20-002423-index.htm |
| 2020-03-23 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320009247/0000899243-20-009247-index.htm |
| 2020-03-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320009250/0000899243-20-009250-index.htm |
| 2020-04-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320010404/0000899243-20-010404-index.htm |
| 2020-04-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320010407/0000899243-20-010407-index.htm |
| 2020-04-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320011277/0000899243-20-011277-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320017347/0000899243-20-017347-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320017353/0000899243-20-017353-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320017354/0000899243-20-017354-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320017355/0000899243-20-017355-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320017356/0000899243-20-017356-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320017357/0000899243-20-017357-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320017361/0000899243-20-017361-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320017363/0000899243-20-017363-index.htm |
| 2020-07-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320018109/0000899243-20-018109-index.htm |
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320018111/0000899243-20-018111-index.htm |
| 2020-10-21 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320028908/0000899243-20-028908-index.htm |
| 2020-10-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1609809/000089924320028909/0000899243-20-028909-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000095010320002661/0000950103-20-002661-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000110465920021149/0001104659-20-021149-index.htm |
| 2020-10-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000110465920113858/0001104659-20-113858-index.htm |
| 2019-09-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000114036119016287/0001140361-19-016287-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000114036120002975/0001140361-20-002975-index.htm |
| 2020-09-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000114036120019924/0001140361-20-019924-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000114420419007781/0001144204-19-007781-index.htm |
| 2018-06-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312518205796/0001193125-18-205796-index.htm |
| 2018-08-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312518235595/0001193125-18-235595-index.htm |
| 2018-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312518240749/0001193125-18-240749-index.htm |
| 2018-09-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312518265488/0001193125-18-265488-index.htm |
| 2018-10-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312518303575/0001193125-18-303575-index.htm |
| 2018-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312518320919/0001193125-18-320919-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312518321819/0001193125-18-321819-index.htm |
| 2018-11-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312518331898/0001193125-18-331898-index.htm |
| 2019-01-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519009357/0001193125-19-009357-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519064643/0001193125-19-064643-index.htm |
| 2019-03-06 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1609809/000119312519065218/0001193125-19-065218-index.htm |
| 2019-03-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519070257/0001193125-19-070257-index.htm |
| 2019-04-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519110877/0001193125-19-110877-index.htm |
| 2019-04-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1609809/000119312519129317/0001193125-19-129317-index.htm |
| 2019-04-30 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1609809/000119312519129353/0001193125-19-129353-index.htm |
| 2019-05-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519133801/0001193125-19-133801-index.htm |
| 2019-06-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1609809/000119312519171388/0001193125-19-171388-index.htm |
| 2019-06-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1609809/000119312519173661/0001193125-19-173661-index.htm |
| 2019-06-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519173673/0001193125-19-173673-index.htm |
| 2019-06-28 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1609809/000119312519186075/0001193125-19-186075-index.htm |
| 2019-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519213482/0001193125-19-213482-index.htm |
| 2019-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519213483/0001193125-19-213483-index.htm |
| 2019-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519283493/0001193125-19-283493-index.htm |
| 2019-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519284005/0001193125-19-284005-index.htm |
| 2019-11-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1609809/000119312519301823/0001193125-19-301823-index.htm |
| 2019-11-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519301827/0001193125-19-301827-index.htm |
| 2019-12-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312519314364/0001193125-19-314364-index.htm |
| 2020-03-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312520057817/0001193125-20-057817-index.htm |
| 2020-03-02 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1609809/000119312520058927/0001193125-20-058927-index.htm |
| 2020-03-09 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1609809/000119312520067187/0001193125-20-067187-index.htm |
| 2020-03-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1609809/000119312520074860/0001193125-20-074860-index.htm |
| 2020-03-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1609809/000119312520077200/0001193125-20-077200-index.htm |
| 2020-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312520077213/0001193125-20-077213-index.htm |
| 2020-03-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312520081498/0001193125-20-081498-index.htm |
| 2020-04-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1609809/000119312520128784/0001193125-20-128784-index.htm |
| 2020-04-30 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1609809/000119312520128794/0001193125-20-128794-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312520135559/0001193125-20-135559-index.htm |
| 2020-06-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312520175590/0001193125-20-175590-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312520214096/0001193125-20-214096-index.htm |
| 2020-08-11 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1609809/000119312520216465/0001193125-20-216465-index.htm |
| 2020-08-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1609809/000119312520216509/0001193125-20-216509-index.htm |
| 2020-08-13 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1609809/000119312520217856/0001193125-20-217856-index.htm |
| 2020-08-13 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1609809/000119312520218233/0001193125-20-218233-index.htm |
| 2020-08-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1609809/000119312520220573/0001193125-20-220573-index.htm |
| 2020-08-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1609809/000119312520220574/0001193125-20-220574-index.htm |
| 2020-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1609809/000119312520220584/0001193125-20-220584-index.htm |
| 2020-08-17 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1609809/000119312520222451/0001193125-20-222451-index.htm |
| 2020-08-19 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1609809/000119312520224776/0001193125-20-224776-index.htm |
| 2019-09-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000121465919005718/0001214659-19-005718-index.htm |
| 2020-09-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1609809/000121465920007732/0001214659-20-007732-index.htm |
| 2018-08-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1609809/000156459018018757/0001564590-18-018757-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1609809/000156459018028339/0001564590-18-028339-index.htm |
| 2019-03-06 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1609809/000156459019006423/0001564590-19-006423-index.htm |
| 2019-05-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1609809/000156459019015070/0001564590-19-015070-index.htm |
| 2019-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1609809/000156459019029069/0001564590-19-029069-index.htm |
| 2019-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1609809/000156459019040255/0001564590-19-040255-index.htm |
| 2020-03-02 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1609809/000156459020008002/0001564590-20-008002-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1609809/000156459020022457/0001564590-20-022457-index.htm |
| 2020-07-28 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1609809/000156459020033715/0001564590-20-033715-index.htm |
| 2020-03-18 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1609809/999999999520000587/9999999995-20-000587-index.htm |
| 2019-04-15 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1609809/999999999719002897/9999999997-19-002897-index.htm |
Seres Therapeutics, Inc (MCRB) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Seres Therapeutics, Inc (MCRB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 926%Institutional Ownership: 8120%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-10-15 | John G. Aunins | Officer | Sell | 14,279.00 | 5.94 | 84,800.13 | 103,811.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318026790/0000899243-18-026790-index.htm |
| 2020-01-26 | John G. Aunins | Chief Technology Officer & EVP | Buy | 12,500.00 | 105,250.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002210/0000899243-20-002210-index.htm | ||
| 2018-09-17 | John G. Aunins | Officer | Sell | 14,279.00 | 7.27 | 103,875.44 | 118,090.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm |
| 2019-11-01 | Marcus Chapman | Officer | Buy | 12,000.00 | 12,000.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924319028069/0000899243-19-028069-index.htm | ||
| 2020-01-26 | Matthew R. Henn | Officer | Buy | 7,500.00 | 12,000.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002211/0000899243-20-002211-index.htm | ||
| 2019-01-28 | Eric D. Shaff | Officer | Sell | 4,378.00 | 5.75 | 25,187.51 | 12,842.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002138/0000899243-19-002138-index.htm |
| 2018-08-15 | John G. Aunins | Officer | Sell | 14,279.00 | 7.57 | 108,069.18 | 132,369.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm |
| 2018-05-15 | John G. Aunins | Officer | Sell | 14,279.00 | 8.08 | 115,400.02 | 146,648.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm |
| 2019-01-26 | DAVID N COOK | Officer | Buy | 7,500.00 | 147,435.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002136/0000899243-19-002136-index.htm | ||
| 2019-01-28 | Thomas DesRosier | Chief Legal Officer and EVP | Sell | 5,471.00 | 5.75 | 31,477.95 | 16,054.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002141/0000899243-19-002141-index.htm |
| 2018-07-15 | John G. Aunins | Chief Technology Officer & EVP | Sell | 14,279.00 | 8.10 | 115,725.58 | 160,927.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318020074/0000899243-18-020074-index.htm |
| 2019-01-26 | Eric D. Shaff | Officer | Buy | 12,000.00 | 17,220.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002138/0000899243-19-002138-index.htm | ||
| 2018-09-07 | Roger Pomerantz | President and CEO | Sell | 1,810.00 | 9.00 | 16,291.27 | 213,976.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318024194/0000899243-18-024194-index.htm |
| 2019-01-26 | Thomas DesRosier | Chief Legal Officer and EVP | Buy | 15,000.00 | 21,525.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002141/0000899243-19-002141-index.htm | ||
| 2018-09-06 | Roger Pomerantz | President and CEO | Sell | 3,013.00 | 9.04 | 27,235.41 | 215,786.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/0000899243-18-023938-index.htm |
| 2018-09-05 | Roger Pomerantz | President and CEO | Sell | 9,505.00 | 9.12 | 86,714.12 | 218,799.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/0000899243-18-023938-index.htm |
| 2018-06-25 | Roger Pomerantz | President and CEO | Sell | 26,752.00 | 9.21 | 246,503.63 | 228,304.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm |
| 2018-06-26 | Roger Pomerantz | President and CEO | Sell | 21,224.00 | 9.19 | 195,133.46 | 228,304.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm |
| 2018-06-27 | Roger Pomerantz | President and CEO | Sell | 16,991.00 | 9.03 | 153,408.34 | 228,304.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm |
| 2018-06-28 | Roger Pomerantz | President and CEO | Sell | 21,560.00 | 9.15 | 197,375.33 | 228,304.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm |
| 2018-06-29 | Roger Pomerantz | President and CEO | Sell | 4,496.00 | 9.10 | 40,915.40 | 228,304.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm |
| 2018-07-06 | Roger Pomerantz | President and CEO | Sell | 15,366.00 | 9.14 | 140,506.70 | 228,304.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm |
| 2018-07-09 | Roger Pomerantz | President and CEO | Sell | 10,981.00 | 9.14 | 100,350.97 | 228,304.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm |
| 2018-07-10 | Roger Pomerantz | President and CEO | Sell | 5,989.00 | 9.05 | 54,207.64 | 228,304.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm |
| 2018-07-11 | Roger Pomerantz | President and CEO | Sell | 1,010.00 | 9.01 | 9,098.99 | 228,304.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/0000899243-18-019814-index.htm |
| 2018-07-11 | Roger Pomerantz | President and CEO | Buy | 1,010.00 | 0.71 | 717.10 | 229,314.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/0000899243-18-019814-index.htm |
| 2018-06-29 | Roger Pomerantz | President and CEO | Buy | 4,496.00 | 0.71 | 3,192.16 | 232,800.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm |
| 2018-07-10 | Roger Pomerantz | President and CEO | Buy | 5,989.00 | 0.71 | 4,252.19 | 234,293.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm |
| 2018-07-09 | Roger Pomerantz | President and CEO | Buy | 10,981.00 | 0.71 | 7,796.51 | 239,285.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm |
| 2018-07-06 | Roger Pomerantz | President and CEO | Buy | 15,366.00 | 0.71 | 10,909.86 | 243,670.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm |
| 2018-06-27 | Roger Pomerantz | President and CEO | Buy | 16,991.00 | 0.71 | 12,063.61 | 245,295.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm |
| 2018-06-26 | Roger Pomerantz | President and CEO | Buy | 21,224.00 | 0.71 | 15,069.04 | 249,528.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm |
| 2018-06-28 | Roger Pomerantz | President and CEO | Buy | 21,560.00 | 0.71 | 15,307.60 | 249,864.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm |
| 2018-06-25 | Roger Pomerantz | President and CEO | Buy | 16,288.00 | 0.71 | 11,564.48 | 255,056.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm |
| 2020-01-26 | Eric D. Shaff | CEO and President | Buy | 20,000.00 | 32,842.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002213/0000899243-20-002213-index.htm | ||
| 2020-01-26 | Thomas DesRosier | Chief Legal Officer and EVP | Buy | 25,000.00 | 41,054.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924320002212/0000899243-20-002212-index.htm | ||
| 2019-06-18 | NOUBAR AFEYAN | Director | Buy | 4,444,444.00 | 2.25 | 9,999,999.00 | 4,444,444.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924319017640/0000899243-19-017640-index.htm |
| 2018-12-17 | John G. Aunins | Chief Technology Officer & EVP | Sell | 14,282.00 | 6.39 | 91,313.40 | 75,250.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/0000899243-18-031411-index.htm |
| 2018-12-19 | John G. Aunins | Chief Technology Officer & EVP | Buy | 10,000.00 | 85,250.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/0000899243-18-031411-index.htm | ||
| 2019-11-22 | Marcus Chapman | Officer | Sell | 3,400.00 | 3.91 | 13,296.72 | 8,600.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924319028069/0000899243-19-028069-index.htm |
| 2018-11-15 | John G. Aunins | Officer | Sell | 14,279.00 | 8.26 | 117,911.70 | 89,532.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924318029310/0000899243-18-029310-index.htm |
| 2019-01-26 | John G. Aunins | Chief Technology Officer | Buy | 7,500.00 | 92,750.00 | https://www.sec.gov/Archives/edgar/data/1609809/000089924319002137/0000899243-19-002137-index.htm |